Human tumor nanoparticles induce apoptosis of pancreatic cancer cells

NewsGuard 100/100 Score

Using nanoparticles made from pieces of tumor cells, investigators from Aix-Marseille University in Marseille, France, have developed a new type of anticancer agent that appears to stop tumor cell growth and proliferation.

This research, led by Dominique Lombardo, Ph.D., and Alain Verine, Ph.D., presents the first evidence that tumor-derived nanoparticles can trigger tumor cell death.

Reporting its work in the FASEB Journal, the investigators began their study by harvesting pieces of tumor cell membrane that bud off from pancreatic cancer cells. These exosomes resemble lipid-based nanoparticles known as liposomes, but the exosomes are loaded with various tumor cell membrane proteins. After purifying the nanoparticles, the researchers administered them to tumor cells, triggering cell death at a level proportional to the amount of nanoparticles added to the cells. The nanoparticles had no effect when added to normal cells.

Further study showed that the nanoparticles were triggering apoptosis, but not via the pathway triggered by most anticancer drugs. The exact mechanism by which the nanoparticles exert their cell-killing activity is still unknown.

This work is detailed in the paper "Human Tumor Nanoparticles Induce Apoptosis of Pancreatic Cancer Cells." An abstract of this paper is available at the journal's Web site. View abstract

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New trials show promise for immune checkpoint blockers in early-stage lung cancer